

Supplementary Table 1. Demographic and patient characteristics according to HMGB1 cellular localization

Characteristics	Cytoplasmic anti-HMGB1 immunoreactivity			P value
	negative (n=72)	0-10% (n=61)	>10% (n=39)	
Age at diagnosis				0.7883
≤40	12 (16.7%)	11 (18%)	7 (17.9%)	
40-65	35 (48.6%)	32 (52.5%)	23 (59%)	
≥65	25 (34.7%)	18 (29.5%)	9 (23.1%)	
TNM				
T				0.4507
T1	33 (45.8%)	33 (54.1%)	15 (38.5%)	
T2	33 (45.8%)	20 (32.8%)	20 (51.3%)	
T3	4 (5.6%)	6 (9.8%)	4 (10.2%)	
T4	2 (2.8%)	2 (3.3%)	0 (0%)	
N				0.6583
N-	46 (63.9%)	35 (57.4%)	22 (56.4%)	
N+	26 (36.1%)	26 (42.6%)	17 (43.6%)	
M				/
M- or Mx	72 (100%)	61 (100%)	39 (100%)	
M+	0 (0%)	0 (0%)	0 (0%)	
Tumor stage (UICC)				0.5173
Stage I	25 (34.7%)	22 (36.1%)	11 (28.2%)	
Stage II	35 (48.6%)	27 (44.2%)	24 (61.6%)	
Stage III	12 (16.7%)	12 (19.7%)	4 (10.2%)	
Stage IV	0 (0%)	0 (0%)	0 (0%)	
Proliferative index				0.8635
≤25%	25 (34.7%)	17 (27.9%)	9 (23.1%)	
26-50%	18 (25%)	16 (26.2%)	12 (30.8%)	
51-75%	16 (22.2%)	13 (21.3%)	8 (20.5%)	
≥75%	13 (18.1%)	15 (24.6%)	10 (25.6%)	
Treatment				0.6919
Radiotherapy	7 (9.7%)	10 (16.4%)	5 (12.8%)	
Chemotherapy	24 (33.3%)	18 (29.5%)	15 (38.5%)	
Chemoradiotherapy	33 (45.8%)	30 (49.2%)	17 (43.5%)	
None	6 (8.4%)	1 (1.6%)	1 (2.6%)	
Unknown	2 (2.8%)	2 (3.3%)	1 (2.6%)	